Hypera (BSP:HYPE3) Debt-to-Equity : 0.79 (As of Mar. 2025)

View and export this data going back to 2008. Start your Free Trial

What is Hypera Debt-to-Equity?

Hypera's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was R$1,890 Mil. Hypera's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was R$7,422 Mil. Hypera's Total Stockholders Equity for the quarter that ended in Mar. 2025 was R$11,738 Mil. Hypera's debt to equity for the quarter that ended in Mar. 2025 was 0.79.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Hypera's Debt-to-Equity or its related term are showing as below:

BSP:HYPE3' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.61 Max: 0.91
Current: 0.79

During the past 13 years, the highest Debt-to-Equity Ratio of Hypera was 0.91. The lowest was 0.05. And the median was 0.61.

BSP:HYPE3's Debt-to-Equity is ranked worse than
80.1% of 814 companies
in the Drug Manufacturers industry
Industry Median: 0.26 vs BSP:HYPE3: 0.79

Hypera Debt-to-Equity Historical Data

The historical data trend for Hypera's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hypera Debt-to-Equity Chart

Hypera Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

0.60

0.75

0.91

0.87

0.78

Hypera Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Debt-to-Equity	Get a 7-Day Free Trial															0.91	0.85	0.88	0.78	0.79

Competitive Comparison of Hypera's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Hypera's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hypera's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hypera's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Hypera's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Hypera Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Hypera's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1409.003	+	7988.364)	/	12096.281
	=	0.78

Hypera's Debt to Equity Ratio for the quarter that ended in Mar. 2025 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1890.119	+	7422.219)	/	11738.29
	=	0.79

Hypera (BSP:HYPE3) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Hypera Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Hypera's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Hypera Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hypera SA (BSP:HYPE3) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

HYPMY:USA

Address

Avenida Magalhaes de Castro, 4800, 240 Floor Continental Tower Building, Bairro Cidade Jardim, Sao Paulo, SP, BRA, CEP 05676-120

Website

https://www.hypermarcas.com.br

Hypera SA is a specialty and generic drug manufacturing company. The company has a focus on the pharmaceutical segments of the Brazilian market, along with a presence in nonprescription drugs and branded generics. Hypermarcas also possesses a share of generic medicines and prescription products. The company also has a wide sales and distribution structure. The Company's operating segments are Consumer Health, Branded Prescription, Similars e Generics, Skincare and the Non-Retail Market.

Hypera Headlines

No Headlines